Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV.
Giuseppe Vittorio De SocioSara TordiDebora AltobelliAnna GidariAnastasia ZoffoliDaniela FrancisciPublished in: Journal of clinical medicine (2023)
Our study shows a similar effectiveness and safety profile in virologically suppressed PLWH switching to DTG/3TC or TAF/FTC/BIC.